NADOLOL (nadolol) by Aurobindo Pharma is adrenergic beta-antagonists [moa]. Approved for beta-adrenergic blocker [epc]. First approved in 2015.
Drug data last refreshed 21h ago
Adrenergic beta-Antagonists
beta-Adrenergic Blocker
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study of Clenbuterol (CST-103) Co-administered With Nadolol (CST-107) in Subjects With Neurodegenerative Disorders
Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
Oral Nadolol for the Treatment of Adults With Mild Asthma
Relative Bioavailability Study of Nadolol (1 x 80 mg) Tablets Under Fasting Conditions
Worked on NADOLOL at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.